Martin F Kaiser
Overview
Explore the profile of Martin F Kaiser including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
62
Citations
2077
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kaiser M, Sonneveld P, Cairns D, Raab M, San-Miguel Izquierdo J, Zhang R, et al.
J Clin Oncol
. 2025 Feb;
:JCO2401253.
PMID: 39965171
Purpose: Survival for patients with multiple myeloma (MM) has improved but outcomes remain heterogeneous. Consistent diagnostic identification of high-risk disease is desirable to address unmet patient need. The aim was...
2.
Jones J, Cairns D, Menzies T, Pawlyn C, Davies F, Sigsworth R, et al.
EClinicalMedicine
. 2023 Aug;
62:102099.
PMID: 37554123
Background: Early trials of long-term lenalidomide use reported an increased incidence of second primary malignancy (SPM), including acute myeloid leukaemia and myelodysplastic syndrome. Later, meta-analysis suggested the link to be...
3.
Kaiser M, Hall A, Walker K, Sherborne A, De Tute R, Newnham N, et al.
J Clin Oncol
. 2023 Jun;
41(23):3945-3955.
PMID: 37315268
Purpose: The multicenter OPTIMUM (MUKnine) phase II trial investigated daratumumab, low-dose cyclophosphamide, lenalidomide, bortezomib, and dexamethasone (Dara-CVRd) before and after autologous stem-cell transplant (ASCT) in newly diagnosed patients with molecularly...
4.
Faustini S, Hall A, Brown S, Roberts S, Hill H, Stamataki Z, et al.
Br J Haematol
. 2023 Mar;
201(5):845-850.
PMID: 36895158
Multiple myeloma (MM) and anti-MM therapy cause profound immunosuppression, leaving patients vulnerable to coronavirus disease 2019 (COVID-19) and other infections. We investigated anti-severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) antibodies longitudinally...
5.
Panopoulou A, Easdale S, Ethell M, Nicholson E, Potter M, Giotas A, et al.
Hemasphere
. 2023 Feb;
7(2):e831.
PMID: 36751511
Refined prediction of early relapse following standard-of-care (SoC) autologous stem cell transplant (ASCT) in newly diagnosed multiple myeloma (NDMM) could inform real-world risk-stratified post-ASCT strategies. We investigated the impact of...
6.
Panopoulou A, Cairns D, Holroyd A, Nichols I, Cray N, Pawlyn C, et al.
Blood
. 2022 Dec;
141(14):1666-1674.
PMID: 36564045
Prediction of individual patient benefit from lenalidomide (Len) maintenance after autologous stem cell transplant (ASCT) remains challenging. Here, we investigated extended molecular profiling for outcome prediction in patients in the...
7.
Jenner M, Pawlyn C, Davies F, Menzies T, Hockaday A, Olivier C, et al.
Br J Haematol
. 2022 Dec;
201(2):267-279.
PMID: 36541152
Lenalidomide is an effective maintenance agent for patients with myeloma, prolonging first remission and, in transplant eligible patients, improving overall survival (OS) compared to observation. The 'Myeloma XI' trial, for...
8.
Went M, Hoang P, Law P, Kaiser M, Houlston R
Sci Rep
. 2022 Jul;
12(1):12696.
PMID: 35882937
Despite recent advances in therapy, multiple myeloma essentially remains an incurable malignancy. Targeting tumour-specific essential genes, which constitute a druggable dependency, potentially offers a strategy for developing new therapeutic agents...
9.
Kaiser M, Boyd K, Koh D, Rata M, Blackledge M, Messiou C
EJHaem
. 2022 Jul;
1(1):361-363.
PMID: 35847719
No abstract available.
10.
Davies F, Pawlyn C, Usmani S, San-Miguel J, Einsele H, Boyle E, et al.
Blood Cancer Discov
. 2022 Jun;
3(4):273-284.
PMID: 35653112
The multiple myeloma treatment landscape has changed dramatically. This change, paralleled by an increase in scientific knowledge, has resulted in significant improvement in survival. However, heterogeneity remains in clinical outcomes,...